		ICIVISE DISCE	OSURE FURIWI
Date	:2022/3/3	1	
			prazan versus proton pump inhibitors in the treatment of
	x esophagitis in China	•	
	uscript number (if known):		
In th	e interest of transparency,	we ask you to disclose all	relationships/activities/interests listed below that are
relat	ed to the content of your n	nanuscript. "Related" mea	ns any relation with for-profit or not-for-profit third
parti	ies whose interests may be	affected by the content of	f the manuscript. Disclosure represents a commitment
-	_	-	If you are in doubt about whether to list a
	ionship/activity/interest, it		•
	following questions apply t uscript only.	o the author's relationship	os/activities/interests as they relate to the current
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup ime frame for disclosure is	· · · · · · · · · · · · · · · · · · ·	in this manuscript without time limit. For all other items,
	caiiic ioi aisciosaic is	the past so months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Takeda (China) International Trading Companyny	prainting of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	X_None	

The south an area sets from time from Tabada (China) between time of Tabadia Communications
The author reports funding from Takeda (China) International Trading Company.

Please place an "X" next to the following statement to indicate your agreement:

	16.032 2.362636012 1.6000
Date:	
Your Name:	Ruixiaotong Sun
Manuscript Title:	Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment o
reflux esophagitis i	n China
Manuscript numbe	r (if known):
parties whose inter to transparency and	ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third ests may be affected by the content of the manuscript. Disclosure represents a commitment d does not necessarily indicate a bias. If you are in doubt about whether to list a y/interest, it is preferable that you do so.
The following quest manuscript only.	tions apply to the author's relationships/activities/interests as they relate to the <u>current</u>
The author's relation	webing (activities (interests should be defined breadly. For evenue, if your manuscript neutrine

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Takeda (China) International Trading Company.	
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	IQVIA(China)	Ruixiaotong Sun is employee of IQVIA(China)

Ruixiaotong Sun is employees of IQVIA(China) and reports funding from Takeda (China) International Trading Company.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/3/31
Your Name:	Yanan Sheng
Manuscript Title:	Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of
reflux esophagitis in	n China
Manuscript number	r (if known):

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	Takeda (China)	
	manuscript (e.g., funding, provision of study materials,	International Trading	
	medical writing, article	Company.	
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V Name	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	Takeda (China) International Trading Company	Yanan Sheng is employee of Takeda

Yanan Sheng is employees of Takeda (China) International Trading Co. Ltd and reports funding from Takeda (China) International Trading Company.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/3/31	
Your Name:	Shuli Qu	
Manuscript Title:	Cost-effectiveness	s analysis of vonoprazan versus proton pump inhibitors in the treatment of
reflux esophagitis ii	n China	
Manuscript numbe	r (if known):	
related to the conte	ent of your manuscrip	ou to disclose all relationships/activities/interests listed below that are ot. "Related" means any relation with for-profit or not-for-profit third by the content of the manuscript. Disclosure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Takeda (China) International Trading Company.	
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	IQVIA(China)	Shuli Qu is employee of IQVIA(China)

Shuli Qu is employee of IQVIA(China) and reports funding from Takeda (China) International Trading Company.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/3/31				
Your Name:	Lu Dong				
Manuscript Title:	Cost-effectivene	ess analysis of vonopraza	an versus proton pui	np inhibitors in the	treatment of
reflux esophagitis i	n China				
Manuscript numbe	r (if known):				
In the interest of tra	ansparency, we ask	you to disclose all relat	ionships/activities/i	nterests listed belov	v that are
related to the conte	ent of your manuscr	ript. "Related" means ar	ny relation with for- _l	profit or not-for-prof	fit third
parties whose inter	ests may be affecte	ed by the content of the	manuscript. Disclosi	are represents a con	nmitment
to transparency and	d does not necessar	ily indicate a bias. If yo	u are in doubt about	whether to list a	
rolationshin/activit	v/interest it is prof	orable that you do so			

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Takeda (China) International Trading Company.	
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time (1997)	26
2		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	Takeda (China) International Trading Company	Lu Dong is employee of Takeda

Lu Dong is employees of Takeda (China) International Trading Co. Ltd and reports funding from Takeda (China) International Trading Company.

Please place an "X" next to the following statement to indicate your agreement:

		ICMJE DISCLO	DSURE FORM
Date	e: 2022/3/3	1	
Your	· Name: Bin W	 'u	
			razan versus proton pump inhibitors in the treatment of
reflu	x esophagitis in China		
Man	uscript number (if known):		
relat parti to tr	ed to the content of your ries whose interests may be ansparency and does not n	nanuscript. "Related" mear affected by the content of	elationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a
	following questions apply t uscript only.	o the author's relationships	s/activities/interests as they relate to the <u>current</u>
to th	e epidemiology of hyperte	·	efined broadly. For example, if your manuscript pertains II relationships with manufacturers of antihypertensive e manuscript.
	em #1 below, report all sup ime frame for disclosure is	•	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	Takeda (China)	
	manuscript (e.g., funding,	International Trading	
	provision of study materials,	Company.	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	X_None	

The south an area sets from time from Tabada (China) between time of Tabadia Communications
The author reports funding from Takeda (China) International Trading Company.

Please place an "X" next to the following statement to indicate your agreement: